Crossmark

The evolving landscape of RAS-targeted therapies

Crossref DOI link: https://doi.org/10.1038/s43018-025-01077-z

Published Online: 2025-12-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Misale, Sandra https://orcid.org/0000-0002-6031-0137
License Information

Text and Data Mining valid from 2025-12-10

Version of Record valid from 2025-12-10
More Information

Article History

First Online: 10 December 2025

Competing interests

: S.M. is a founder and scientific advisor of Thera65, is a consultant to Merck, and receives research funding from AstraZeneca.